Jenburkt Pharmaceuticals Ltd vs Lasa Supergenerics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Jenburkt Pharmaceuticals Ltd is ₹ 1150 as of 06 May 15:30 . The P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 11.1 on March 2021 to 13.9 on March 2025 . This represents a CAGR of 4.60% over 5 yearsThe P/E Ratio of Lasa Supergenerics Ltd changed from 10.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 182.84 crore on March 2021 to ₹ 446.49 crore on March 2025 . This represents a CAGR of 19.55% over 5 yearsThe Market Cap of Lasa Supergenerics Ltd changed from ₹ 243.63 crore on March 2021 to ₹ 84.42 crore on March 2025 . This represents a CAGR of -19.10% over 5 years The revenue of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 48.98 crore as compare to the Dec '25 revenue of ₹ 44.84 crore. This represent the growth of 9.23% The revenue of Lasa Supergenerics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 2.22 crore. This represent the decline of -100% The ebitda of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 14.65 crore as compare to the Dec '25 ebitda of ₹ 9.24 crore. This represent the growth of 58.55% The ebitda of Lasa Supergenerics Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -0.73 crore. This represent the decline of -100% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 7.42 crore to ₹ 10.85 crore over 8 quarters. This represents a CAGR of 20.92% The net profit of Lasa Supergenerics Ltd changed from ₹ -2.73 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 yearsThe Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

FAQs for the comparison of Jenburkt Pharmaceuticals Ltd and Lasa Supergenerics Ltd

Which company has a larger market capitalization, Jenburkt Pharmaceuticals Ltd or Lasa Supergenerics Ltd?

Market cap of Jenburkt Pharmaceuticals Ltd is 507 Cr while Market cap of Lasa Supergenerics Ltd is 41 Cr

What are the key factors driving the stock performance of Jenburkt Pharmaceuticals Ltd and Lasa Supergenerics Ltd?

The stock performance of Jenburkt Pharmaceuticals Ltd and Lasa Supergenerics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jenburkt Pharmaceuticals Ltd and Lasa Supergenerics Ltd?

As of May 7, 2026, the Jenburkt Pharmaceuticals Ltd stock price is INR ₹1150.9. On the other hand, Lasa Supergenerics Ltd stock price is INR ₹8.25.

How do dividend payouts of Jenburkt Pharmaceuticals Ltd and Lasa Supergenerics Ltd compare?

To compare the dividend payouts of Jenburkt Pharmaceuticals Ltd and Lasa Supergenerics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.